A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal approval, but questions have emerged about the extent to which such tests can accurately predict whether a cognitively healthy person will develop cognitive impairment—a key symptom of Alzheimer’s disease.
Please follow and like us:
